6results about How to "Prolong life" patented technology

Provided are a steel material and a method for producing the same. The steel material exhibits excellent hydrogen embrittlement resistance in a high-pressure hydrogen gas environment and is, therefore, suitable for use in hydrogen storage tanks, hydrogen line pipes, and the like. A steel material for a high-pressure hydrogen gas environment has a predetermined chemical composition. The steel material has a tensile strength of 560 MPa or higher, and a fracture toughness value KIH exhibited by the steel material in a high-pressure hydrogen gas atmosphere is 40 MPa ·m1 / 2 or higher.

The present invention pertains to a negative electrode for a lithium secondary battery, a method for manufacturing same, and a lithium secondary battery including same. More specifically, the negative electrode for a lithium secondary battery according to the present invention has a protective layer containing a three-dimensional structure composed of metal and lithium nitride, and thus uniform ionic conductivity and electrical conductivity can be induced on the surface of the negative electrode.

This invention discloses the preparation and application of radiofrequency thermoresponsive platinum ion crosslinked black phosphorus nanogel. The nanogel has a core-shell structure, comprising a core composed of a radiofrequency thermosensitive agent and chemotherapeutic drugs, and a shell constructed from a thermosensitive nanopolymer. The thermosensitive nanogel BP-Pt@PNA prepared using the above components exhibits radiofrequency thermosensitive properties. Simultaneously, the introduction of the thermosensitive nanopolymer improves the stability of the radiofrequency thermosensitive agent and chemotherapeutic drugs, enabling long-term drug retention and fully leveraging the synergistic effect of non-invasive radiofrequency thermotherapy and chemotherapy. This drug-loaded nanogel can achieve multimodal treatment applications, including non-invasive radiofrequency thermotherapy-chemotherapy synergistic antitumor therapy and invasive radiofrequency ablation-chemotherapy-vascular embolization synergistic antitumor therapy, demonstrating significant clinical translational potential.

This invention relates to the synergistic anticancer application of redox-responsive condensates (FFSSFF) for delivering jujube extract and 3-methyladenine. Specifically, this invention relates to the application of redox-responsive condensates in the preparation of targeted drug delivery products, wherein the targeted drug delivery products release drugs in response to glutathione. The active ingredients in the targeted drug delivery products are jujube extract and 3-methyladenine. This invention utilizes an FFSSFF carrier designed based on the LLPS principle, integrating redox-sensitive disulfide bond linkage modules to achieve spatiotemporally controlled drug delivery within a tumor tissue-specific microenvironment with high glutathione concentrations.

The application discloses application of Hsap_1847317_1SS12GA_R+1 in preparation of a product for detecting tumor immunotherapy drug resistance, the immunotherapy is an immune checkpoint inhibitor treatment, and a nucleotide sequence of the Hsap_1847317_1SS12GA_R+1 is shown as SEQ ID NO. 1. In the technical scheme provided by the application, through a three-stage research process of screening-training-verification, it is found for the first time that Hsap_1847317_1SS12GA_R+1 is closely related to non-small cell lung cancer immunotherapy drug resistance, and it is confirmed that the Hsap_1847317_1SS12GA_R+1 can be used as an efficient detection marker. Research results show that in blood of patients after immunotherapy drug resistance, the expression amount of the Hsap_1847317_1SS12GA_R+1 is significantly up-regulated by about 10 times (P<0.0001), and excellent statistical significance is shown.